If CA IX and CA XII are involved in the development of AML drug resistance, then patients failing induction chemotherapy as demonstrated by an interim BM assessment routinely performed 14–21 days after the initiation of therapy should show persistent or enhanced CA IX and/or CA XII staining when compared to the diagnostic marrow. The gene discussed is CA12; the disease is acute myeloid leukemia.